Skip to main content

Table 3 Use of drugs, non-pharmacological treatments, and complementary tests during the study by treatment group

From: A Cost-Consequences analysis of the effect of Pregabalin in the treatment of peripheral Neuropathic Pain in routine medical practice in Primary Care settings

Resource Non-PGB
(N = 157)§
PGB monotherapy
(N = 577)§
PGB add-on
(N = 575)§
p between groups
  Baseline Final Baseline Final Baseline Final Baseline Final$
Drug treatment
Mean number (SD) 2.4 (1.3) 2.2 (1.2) 2.0 (1.1) 1.0 (0.0)* 2.6 (1.4) 2.7 (1.0) <0.001 <0.001
Non-pharmacological treatments; N (%)
   Physiotherapy 45 (30.8) 23 (15.8)* 168 (34.1) 73 (14.8)* 194 (38.2) 116 (22.8)* 0.180 0.011
   TENS 16 (11.4) 12 (8.6) 45 (9.6) 24 (5.1)* 52 (10.7) 32 (6.6) 0.766 0.375
   Infiltrations 21 (14.9) 11 (7.8) 51 (10.8) 20 (4.2)* 72 (14.8) 21 (4.3)* 0.154 0.195
   Electrotherapy 18 (12.9) 10 (7.1) 30 (6.5) 12 (2.6)* 48 (10.0) 17 (3.6)* 0.033 0.190
   Blockade 3 (2.2) 1 (0.7) 8 (1.7) 4 (0.9) 5 (1.1) 2 (0.4) 0.552 0.858
   Iontophoresis 4 (2.9) 0 (0.0) 1 (0.2) 0 (0.0) 7 (1.5) 1 (0.2) 0.019 0.530
   Spinal stimulator 1 (0.7) 0 (0.0) 2 (0.4) 1 (0.2) 4 (0.8) 2 (0.4) 0.727 0.700
   Pumps 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.6) 0 (0.0) 0.214 1.000
   Hydrotherapy 3 (1.8) 0 (0.0) 10 (1.7) 9 (1.5) 15 (2.5) 7 (1.2) 0.552 0.199
   Short wave 3 (1.8) 1 (0.6) 7 (1.2) 1 (0.2) 22 (3.7) 12 (2.0) 0.013 0.053
   Magnetotherapy 1 (0.6) 3 (1.8) 3 (0.5) 2 (0.3) 6 (1.0) 2 (0.3) 0.568 0.034
   Acupuncture 1 (0.6) 0 (0.0) 4 (0.7) 0 (0.0) 3 (0.5) 0 (0.0) 0.938 1.000
Complementary tests; N (%)
   CT 25 (15.0) 17 (10.2) 155 (25.9) 39 (6.5)* 193 (32.8) 69 (11.7)* <0.001 0.013
   Resonance 60 (35.9) 32 (19.2)* 193 (32.3) 62 (10.4)* 224 (38.0) 88 (14.9)* 0.114 0.012
   Electromyogram 40 (24.0) 22 (13.2) 164 (27.4) 51 (8.5)* 215 (36.5) 68 (11.5)* 0.001 0.109
   ECHO Doppler 12 (7.2) 8 (4.8) 50 (8.4) 14 (2.3)* 59 (10.0) 20 (3.4) 0.424 0.194
   Thermogram 6 (3.6) 1 (0.6) 4 (0.7) 3 (0.5) 13 (2.2) 10 (1.7) 0.016 0.151
   X-rays 111 (66.5) 51 (30.5)* 363 (60.7) 123 (20.6)* 410 (69.6) 145 (24.6)* 0.005 0.058
   General analysis 124 (74.3) 73 (43.7)* 427 (71.4) 198 (33.1)* 450 (76.4) 233 (39.6)* 0.146 0.032
   Gammagram 12 (7.2) 5 (3.0) 41 (6.9) 11 (1.8)* 51 (8.7) 24 (4.1)* 0.491 0.129
  1. SD: standard deviation; TENS: Transcutaneous electric neurostimulation; CT: Computerized tomography; * p < 0.0001; p < 0.001; p<0.05 vs. intragroup baseline value. §Total number of analyzed patients; some patients did not report all data. $Between groups changes comparison adjusted by baseline values and number of previous drugs.